Compare BridgeBio Pharma Inc (BBIO) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs SkyWest Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while SkyWest Inc trades at $107.91 (market cap $4.18B). The key difference: BridgeBio Pharma Inc is far larger — about 4× SkyWest Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | SKYW | |
|---|---|---|
Market Cap | $16.61B | $4.18B |
Sector | Health | Technology |
52-Week High | $90.17 | $123.72 |
52-Week Low | $47.29 | $78.40 |
Enterprise Value | $18.16B | $5.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SkyWest (SKYW) trades at $111.84, down 1.41% on the day, with a bullish technical signal supported by moving averages and a consensus analyst buy rating. Recent Q2 2026 earnings missed estimates at $2.54 EPS versus $2.70 expected, but revenue trends show growth to $4.2B in 2026. The stock benefits from strong profitability with a 9.78% net margin and attractive valuation metrics, including a P/E of 10.69. Key developments include executive stock sales and a 7.7% post-earnings rally noted by Zacks on July 27, 2026.
Outlook remains positive due to undervaluation and fleet expansion, but risks include fuel cost volatility from Iran war impacts (New York Post, July 7, 2026) and insider selling. The consensus price target of $109.33 suggests limited upside, with execution on earnings beats being critical for further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
